China
Bridgewater Widens Lead in China Race as Returns Outclass Rivals
Bridgewater All Weather Plus No. 2 fund up 11% through August
American Business Confidence in China Slumps to Lowest in Decades
U.S. companies are painting the bleakest picture in decades over doing business in China as tensions between Beijing and the West are compounded by a deteriorating environment for their operations.
BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China
Wanchunbulin, BeyondSpring’s 58%-owned subsidiary in China, to partner with Hengrui, the leader in oncology product R&D and commercialization in China, for the exclusive commercial and co-development rights for plinabulin in Greater China markets (“the Territory”)
又有两家Biotech，出事了
9月15日，“医药一哥”恒瑞医药子公司瑞石生物被传“解散”的消息愈演愈烈，财联社记者通过独家现场走访和多方采访核实获悉，当日下午瑞石生物已经召集员工会议，会上明确否认了外界关于公司“解散”的传闻，并通报了股东大会决议，包括中止经营活动、遣散部分员工等，相关遣散方案正在制定中。
Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius’ novel anti-PD-1 mAb HANSIZHUANG in MENA
Shanghai Henlius Biotech, Inc. (2696.HK) has entered into an exclusive license agreement with PT Kalbe Genexine Biologics ("KGbio"), an Indonesian pharmaceutical company and a holding subsidiary to PT Kalbe Farma, Tbk ("Kalbe"), for the development and commercialisation of HANSIZHUANG (serplulimab injection) as a treatment for two indications including ES-SCLC, Henlius' novel anti-PD-1 mAb, in 12 Middle East and North African (MENA) countries including Saudi Arabia, the United Arab Emirates, Egypt, Qatar, Jordan, Morocco, etc.
科律助力宜明昂科成功香港上市
宜明昂科生物医药技术（上海）股份有限公司（以下简称“宜明昂科”，股票代码：1541.HK）于今日在香港联合交易所主板正式挂牌上市。科律律师事务所（Cooley LLP）作为宜明昂科的国际律师，为公司的成功上市全程提供法律服务。
China to Set Up New Agency to Promote Private Sector Growth
China’s top economic planner is creating a new department to help private businesses, the latest step by the government to revive confidence in the sector and bolster growth.
Cantor Fitzgerald Bolsters Healthcare and Biotechnology Equity Research Team with Addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D.
Cantor Fitzgerald, L.P., ("Cantor") a leading global financial services firm, today announced the addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D., to its Healthcare and Biotechnology Research platform.
China: The latest medtech access policies and implications
In May 2023, NHSA indicated a change of direction from top-down management to a bottom-up approach, issuing policies requesting NRMDL to be established in all provinces by 2025.
